Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Core Laboratories N.V. (CLB - Analyst Report) has reported impressive second quarter 2011 results, driven by commendable performances across all the three business units.
Earnings per share (EPS), excluding special items, came in at 90 cents, moving ahead of the Zacks Consensus Estimate of 88 cents. Moreover, EPS increased 27% from 71 cents in the second quarter of 2010.
Total revenue for the quarter was $225.8 million, up 13.5% from $198.9 million in the prior-year quarter, aided by strong growth in all business units.
The quarter’s results were influenced by various development projects across deepwater offshore West and East Africa, Middle East and Asia Pacific belt. Strong contributions from the Eagle Ford, Niobrara and Granite Wash shale plays also boosted Core Laboratories’ performance.
Reservoir Description Segment
Revenues at the Reservoir Description segment (which focuses on international crude oil related projects) upped 11.5% year over year to $118.8 million. Operating income for the unit grew 21% year over year to $30.3 million, with the operating margin coming in at 26%. The improvement was attributable to the start-up of various international projects as well as deepwater offshore crude-oil-related ventures.
Production Enhancement Segment
Core Laboratories’ Production Enhancement revenues leaped 11.4% year over year to $88.8 million while operating income declined 6.1% year over year to $24.5 million. Operating margin came at an impressive 28%, buoyed by the greater market share of the HTD Blast perforating system and high demand for advanced technologies.
Reservoir Management Segment
Revenues from Reservoir Management operations was $18.2 million, up 43.3% year over year while operating income escalated 97.3% year over year to $7.3 million, reflecting encouraging results from the company’s global projects. Operating margin for the quarter was 40%.
Balance Sheet, Free Cash Flow & Share Buyback
As of June 30, 2011, Core Laboratories had cash and cash equivalents of $24.6 million. Capital expenditures for the second quarter were $7.6 million. The company generated free cash flow of $32.3 million or $0.66 per diluted share.
Quarterly Dividend
On July 12, 2011, Core’s board announced a cash dividend of 25 cents per share (amounting to an annualized payout of $1.00 per share) of common stock, payable on August 22, 2011 to shareholders of record on July 22, 2011.
Guidance
The company expects third quarter 2011 revenues of approximately $230 million to $245 million and earnings in the range of 98 cents to $1.00 per share.
For 2011, Core Laboratories forecast total revenue in a $910 million to $930 million range, while earnings will likely be $3.65 to $3.72 per share, up from previous forecast of $3.55 to $3.60.
Management remains optimistic that performance in the second half of 2011 will likely be fueled by strong international and deepwater offshore activity.
Our Take
Amsterdam, Netherlands-based Core Laboratories enjoys a leadership position in the reservoir optimization niche, along with a global footprint and deep portfolio of proprietary products and services.
However, our long-term recommendation on the stock remains Neutral, given the company’s vulnerability to gas/oil price volatility, geo-political risks, competition and the advent of new technologies. The company faces competition from peers, such as Baker Hughes Incorporated (BHI - Analyst Report) and Halliburton Company (HAL - Analyst Report).
Core Laboratories currently retains a Zacks #3 Rank (short-term Hold rating).
Get the full Analyst Report on BHI - FREE
Get the full Analyst Report on HAL - FREE
Get the full Analyst Report on CLB - FREE